See the DrugPatentWatch profile for Remicade
When does Remicade (infliximab) lose patent protection?
Remicade (infliximab) was first approved in the late 1990s, and the original U.S. patent estate for infliximab is widely considered to be past its main expirations. Today, multiple infliximab biosimilars are available in the U.S., which strongly indicates that exclusivity and the most relevant primary patent barriers have already expired.
For a current, drug-by-drug view of the infliximab patent landscape (including specific expiration dates and any later “evergreening” patents), DrugPatentWatch.com is the most direct place to check. [1]
Are infliximab biosimilars allowed to compete already?
Yes. Infliximab biosimilars are on the market in the U.S., meaning regulatory pathways have already cleared after exclusivity/patent limitations for the reference product. That competitive status generally reflects that Remicade’s key patent protections are no longer preventing biosimilar approval.
For up-to-date competitive and patent-status context, see the infliximab entry on DrugPatentWatch.com. [1]
What can still remain protected even after main patent expiration?
Even when major patents expire, there can still be additional, later-expiring patents tied to specific claims (for example, formulation, dosing regimens, or manufacturing-related claims). These may not block all biosimilar entry, but they can affect which products and labeling are permitted, or whether certain competitors face litigation.
DrugPatentWatch.com tracks this type of “latest-to-expire” patent detail for each drug name and formulation, which is useful when you want the expiration status beyond the headline. [1]
How to verify the exact “expiration status” you care about (U.S. vs global)
Patent expiration timing differs by country, and “expiration” can mean different things: the last patent to expire, patent settlement-triggered stays, or regulatory exclusivity periods. If you need an exact answer for a particular geography (U.S., EU, UK, etc.) and a particular Remicade product version, the patent-by-patent schedule on DrugPatentWatch.com is the fastest way to confirm.
DrugPatentWatch.com: Remicade / infliximab patent expiration tracking. [1]
Sources
[1] https://www.drugpatentwatch.com/